These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 26938947

  • 1. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
    Eom HS, Choi BK, Lee Y, Lee H, Yun T, Kim YH, Lee JJ, Kwon BS.
    J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
    [Abstract] [Full Text] [Related]

  • 2. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy.
    Choi BK, Lee SC, Lee MJ, Kim YH, Kim YW, Ryu KW, Lee JH, Shin SM, Lee SH, Suzuki S, Oh HS, Kim CH, Lee DG, Hwang SH, Yu EM, Lee IO, Kwon BS.
    J Immunother; 2014 May; 37(4):225-36. PubMed ID: 24714356
    [Abstract] [Full Text] [Related]

  • 3. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
    Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM.
    Clin Cancer Res; 2014 Oct 01; 20(19):5009-22. PubMed ID: 25124688
    [Abstract] [Full Text] [Related]

  • 4. Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.
    Burns DM, Ryan GB, Harvey CM, Nagy E, Hughes S, Murray PG, Russell NH, Fox CP, Long HM.
    Front Immunol; 2019 Oct 01; 10():2489. PubMed ID: 31736946
    [Abstract] [Full Text] [Related]

  • 5. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, Onoda H, Yatabe Y, Ito M, Miyamura K, Nagai H, Moritani S, Sugiura I, Tsushita K, Mihara H, Ohbayashi K, Iba S, Emi N, Okamoto M, Iwata S, Kimura H, Kuzushima K, Morishima Y.
    Leuk Lymphoma; 2015 Apr 01; 56(4):1072-8. PubMed ID: 24975317
    [Abstract] [Full Text] [Related]

  • 6. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P.
    J Immunother; 2007 Apr 01; 30(8):817-24. PubMed ID: 18049333
    [Abstract] [Full Text] [Related]

  • 7. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S.
    J Clin Oncol; 2005 Dec 10; 23(35):8942-9. PubMed ID: 16204009
    [Abstract] [Full Text] [Related]

  • 8. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
    Zheng Y, Parsonage G, Zhuang X, Machado LR, James CH, Salman A, Searle PF, Hui EP, Chan AT, Lee SP.
    Cancer Immunol Res; 2015 Oct 10; 3(10):1138-47. PubMed ID: 25711537
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.
    J Immunol Methods; 2014 Jun 10; 408():101-13. PubMed ID: 24877879
    [Abstract] [Full Text] [Related]

  • 10. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
    McLaughlin LP, Gottschalk S, Rooney CM, Bollard CM.
    Methods Mol Biol; 2017 Jun 10; 1532():255-265. PubMed ID: 27873282
    [Abstract] [Full Text] [Related]

  • 11. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y, Aïssi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D.
    Cytotherapy; 2014 Jan 10; 16(1):122-34. PubMed ID: 24094498
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S.
    Cytotherapy; 2019 Feb 10; 21(2):212-223. PubMed ID: 30396848
    [Abstract] [Full Text] [Related]

  • 13. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
    Klatt T, Ouyang Q, Flad T, Koetter I, Bühring HJ, Kalbacher H, Pawelec G, Müller CA.
    J Rheumatol; 2005 Feb 10; 32(2):239-51. PubMed ID: 15693083
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.
    Eur J Immunol; 2006 Mar 10; 36(3):593-602. PubMed ID: 16479544
    [Abstract] [Full Text] [Related]

  • 15. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
    Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M.
    Blood; 2010 Nov 11; 116(19):3695-704. PubMed ID: 20671118
    [Abstract] [Full Text] [Related]

  • 16. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G, Hamidou MA, Clémenceau B, Gaschet J, Tiberghien P, Ferrand C, Vivien R, Barbarot S, Coste-Burel M, Moreau A, Vié H.
    Clin Immunol; 2006 Apr 11; 119(1):79-86. PubMed ID: 16386957
    [Abstract] [Full Text] [Related]

  • 17. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Fogg MH, Wirth LJ, Posner M, Wang F.
    Proc Natl Acad Sci U S A; 2009 Mar 03; 106(9):3318-23. PubMed ID: 19211798
    [Abstract] [Full Text] [Related]

  • 18. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas.
    Cho HI, Hong YS, Lee MA, Kim EK, Yoon SH, Kim CC, Kim TG.
    Int J Hematol; 2006 Jan 03; 83(1):66-73. PubMed ID: 16443556
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP.
    Cancer Res; 2001 Aug 15; 61(16):6219-26. PubMed ID: 11507075
    [Abstract] [Full Text] [Related]

  • 20. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.
    Oncol Rep; 2004 Oct 15; 12(4):725-31. PubMed ID: 15375491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.